Pregnancy and Lactation Product Included in Labor Day Promotion
COLUMBIA, Md., Aug. 29 /PRNewswire-FirstCall/ -- Martek Biosciences Corporation (Nasdaq: MATK) announced today that Mead Johnson Nutritionals has introduced two new products to its Enfamil(R) LIPIL(R) line of infant formulas. The new products, Enfamil(R) Premature LIPIL(R) and Enfamil(R) EnfaCare(R) LIPIL(R), have recently received clearance from the United States Food and Drug Administration (FDA).
All of Mead Johnson's LIPIL products contain a blend of Martek's docosahexaenoic acid (DHA) and arachidonic acid (ARA), two nutrients that are key building blocks of an infant's brain and visual system and are naturally present in breast milk. Clinical studies have demonstrated numerous benefits for those premature infants receiving DHA and ARA-supplemented formula.
Enfamil Premature LIPIL is now available in hospitals nationwide. Enfamil EnfaCare LIPIL, for premature infants who have left the hospital, but still require the extra calories, nutrients and minerals of a specialized formula, will be available in stores later this fall.
In related news, Mead Johnson has designated Labor Day 2002 as "LIPIL Day." In conjunction with this announcement, Mead Johnson will provide mothers giving birth on this Labor Day a choice of one free case of Enfamil LIPIL with Iron or a free two-month supply of Neuromins(R) PL. Neuromins PL is a dietary supplement of DHA manufactured by Martek for pregnant and lactating women. Neuromins PL supports the maternal intake of DHA, helping to ensure that breastfeeding mothers receive necessary levels of the nutrient. For more information on this offer, please visit Mead Johnson's Enfamil web site at http://www.enfamil.com.
Martek Biosciences Corporation develops, manufactures and sells products from microalgae. The Company's products include: (1) specialty, nutritional oils for infant formula that aid in the development of the eyes and central nervous system in newborns; (2) nutritional supplements and food ingredients that may play a beneficial role in promoting mental and cardiovascular health throughout life; and (3) new, powerful fluorescent markers for diagnostics, rapid miniaturized screening, and gene and protein detection.
This press release contains forward-looking statements regarding the commercialization of Martek's products. Such statements involve risks and uncertainties that could cause future actual results to differ due to a variety of risk factors, including without limitation those factors set forth in Martek's filings with the Securities and Exchange Commission.